These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 33343822)

  • 1. Gavreto,
    Am Health Drug Benefits; 2020; 13(5):213-215. PubMed ID: 33343822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with
    Digumarthy SR; Mendoza DP; Lin JJ; Rooney M; Do A; Chin E; Yeap BY; Shaw AT; Gainor JF
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
    Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
    Kohno T; Nakaoku T; Tsuta K; Tsuchihara K; Matsumoto S; Yoh K; Goto K
    Transl Lung Cancer Res; 2015 Apr; 4(2):156-64. PubMed ID: 25870798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entrectinib OK'd for Cancers with
    Cancer Discov; 2019 Oct; 9(10):OF2. PubMed ID: 31471291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful long-term treatment of non-small cell lung cancer positive for
    Takeda M; Sakai K; Nishio K; Nakagawa K
    Onco Targets Ther; 2019; 12():5355-5358. PubMed ID: 31360064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of RET fusions in advanced colorectal cancer.
    Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
    Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
    Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kato S; Subbiah V; Marchlik E; Elkin SK; Carter JL; Kurzrock R
    Clin Cancer Res; 2017 Apr; 23(8):1988-1997. PubMed ID: 27683183
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
    Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
    Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub.
    Das TK; Cagan RL
    Cell Rep; 2017 Sep; 20(10):2368-2383. PubMed ID: 28877471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Zhang Q; Xu C; Wang W; Wu M; Zhu Y; Zhuang W; Du K; Huang Y; Chen Y; Wu B
    Med Sci Monit; 2018 Nov; 24():8207-8212. PubMed ID: 30429449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
    Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
    J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?
    Skálová A; Ptáková N; Santana T; Agaimy A; Ihrler S; Uro-Coste E; Thompson LDR; Bishop JA; Baněčkova M; Rupp NJ; Morbini P; de Sanctis S; Schiavo-Lena M; Vanecek T; Michal M; Leivo I
    Am J Surg Pathol; 2019 Oct; 43(10):1303-1313. PubMed ID: 31162284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.